Brokerages predict that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will post sales of $27.26 million for the current quarter, according to Zacks. Two analysts have made estimates for Enanta Pharmaceuticals’ earnings, with estimates ranging from $23.97 million to $30.56 million. Enanta Pharmaceuticals posted sales of $10.42 million during the same quarter last year, which would indicate a positive year over year growth rate of 161.6%. The company is expected to report its next earnings report on Wednesday, February 14th.
On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $27.26 million for the current financial year, with estimates ranging from $69.44 million to $97.28 million. For the next financial year, analysts expect that the business will report sales of $0.00 per share. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business had revenue of $75.93 million for the quarter, compared to analysts’ expectations of $73.80 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 491.3% on a year-over-year basis.
A number of research firms recently weighed in on ENTA. Royal Bank of Canada lowered shares of Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a research note on Tuesday, January 2nd. TheStreet upgraded shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Wednesday, December 13th. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, JMP Securities upped their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research note on Wednesday, October 4th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Enanta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $45.25.
Enanta Pharmaceuticals (NASDAQ ENTA) traded up $1.32 during mid-day trading on Thursday, hitting $67.32. 93,472 shares of the company were exchanged, compared to its average volume of 120,295. Enanta Pharmaceuticals has a 12-month low of $25.92 and a 12-month high of $67.41. The stock has a market capitalization of $1,287.56, a price-to-earnings ratio of 76.50 and a beta of 0.64.
Several hedge funds have recently added to or reduced their stakes in ENTA. SG Americas Securities LLC boosted its holdings in Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Enanta Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after purchasing an additional 304 shares in the last quarter. Thrivent Financial For Lutherans boosted its holdings in Enanta Pharmaceuticals by 7.3% in the second quarter. Thrivent Financial For Lutherans now owns 8,410 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 570 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Enanta Pharmaceuticals by 7.9% in the second quarter. Parametric Portfolio Associates LLC now owns 12,787 shares of the biotechnology company’s stock valued at $460,000 after purchasing an additional 933 shares in the last quarter. Finally, Voya Investment Management LLC boosted its holdings in Enanta Pharmaceuticals by 13.3% in the second quarter. Voya Investment Management LLC now owns 8,350 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 977 shares in the last quarter. Hedge funds and other institutional investors own 66.83% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $27.26 Million” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/zacks-analysts-expect-enanta-pharmaceuticals-inc-enta-will-announce-quarterly-sales-of-27-26-million.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.